MUMBAI, India, Jan. 9 -- Intellectual Property India has published a patent application (202521107041 A) filed by LNCT University, Bhopal, Madhya Pradesh, on Nov. 5, 2025, for 'topical hydrogel composition of acyclovir containing honey, carbopol, and chitosan for sustained release.'
Inventor(s) include Mrs Purnima Tripathi; and Dr. Akhlesh Kumar Singhai.
The application for the patent was published on Dec. 12, under issue no. 50/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a topical hydrogel formulation comprising Acyclovir, Chitosan, Carbopol 934, and Honey, designed for sustained antiviral therapy. The hydrogel provides controlled release of Acyclovir, enhancing its therapeutic efficacy against herpes simplex and varicella-zoster infections while minimizing systemic side effects. The formulation incorporates Chitosan for bioadhesion and controlled release, Carbopol 934 for structural integrity, and Honey for antimicrobial and wound-healing properties. Optimized using a Box-Behnken Design, the hydrogel exhibits skin-compatible pH (6.7-7.2), suitable viscosity (5300-6700 cps), excellent spreadability, and extrudability, ensuring ease of topical application. In-vitro studies demonstrate sustained drug release over 12-24 hours following first-order and Korsmeyer-Peppas kinetics, while stability studies confirm retention of 95% drug content over 90 days. The invention provides a stable, effective, and patient-compliant hydrogel system for topical antiviral treatment."
Disclaimer: Curated by HT Syndication.
